[HTML][HTML] Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection
I Esposito, S Marciano, L Haddad, O Galdame… - Viruses, 2018 - mdpi.com
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
[HTML][HTML] Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus …
I Esposito, S Marciano, L Haddad, O Galdame… - Viruses, 2019 - ncbi.nlm.nih.gov
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
I Esposito, S Marciano, L Haddad… - Viruses (1999 …, 2019 - search.ebscohost.com
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection
I Esposito, S Marciano, L Haddad, O Galdame… - 2019 - ri.conicet.gov.ar
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection
I Esposito, S Marciano, L Haddad, O Galdame… - 2019 - datosdeinvestigacion.conicet.gov.ar
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
[PDF][PDF] Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection
I Esposito, S Marciano, L Haddad, O Galdame… - core.ac.uk
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection.
I Esposito, S Marciano, L Haddad, O Galdame… - 2019 - cabidigitallibrary.org
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection
I Esposito, S Marciano, L Haddad, O Galdame… - …, 2019 - search.proquest.com
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection
I Esposito, S Marciano, L Haddad, O Galdame… - …, 2018 - pubmed.ncbi.nlm.nih.gov
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection
I Esposito, S Marciano, L Haddad, O Galdame… - 2019 - notablesdelaciencia.conicet.gov.ar
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …